Skip to main content

Table 4 Predictive performance of CSF biomarkers for clinical progression among 139 samples

From: Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans

Clinical variables

Biomarkers

Aβ42

T-tau

P-tau

Aβ42/Aβ40

t-tau/Aβ42

p-tau/Aβ42

F, P value

CDR

4.139, 0.008

1.512, 0.215

1.127, 0.341

3.627, 0.015

2.831, 0.041

3.639, 0.015

CDR-SB

8.308, 0.0001

1.584, 0.197

1.011, 0.390

5.982, 0.001

4.472, 0.005

6.416, 0.0001

BDS-ADL

3.471, 0.018

1.634, 0.185

0.749, 0.525

2.975, 0.034

2.199, 0.092

3.095, 0.030

SBT

1.566, 0.201

1.500, 0.218

0.661, 0.578

2.002, 0.117

2.365, 0.074

1.720, 0.167

MMSE

3.434, 0.020

2.362, 0.076

1.358, 0.260

4.227, 0.007

4.277, 0.007

5.030, 0.003

Constructional praxis

2.921, 0.038

1.596, 0.195

0.335, 0.800

2.071, 0.109

2.244, 0.088

2.088, 0.107

Clock drawing

3.295, 0.024

3.482, 0.019

1.356, 0.261

4.751, 0.004

5.091, 0.003

5.034, 0.003

  1. Ten subjects with AD-like CSF signature (2, 1, and 7 at first, second, and third follow-ups, respectively) and 9 subjects with normal CSF signature (1, 4, and 4 at third, second, and first follow-ups, respectively) were lost to follow-up. Numbers in bold indicate the variables with significance under ANCOVA analysis
  2. CDR Clinical Dementia Rating scale, CDR-SB CDR-Sum of Boxes, BDS-ADL Blessed Dementia Scale-Activities of Daily Living, SBT Short Blessed Test, MMSE Mini-Mental State Examination
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193